UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2018-10, Vol.29 (Supplement_4), p.iv238-iv255

2018

Volltextzugriff (PDF)

Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies

Oncogene, 2013-10, Vol.32 (41), p.4861-4870

2013

Volltextzugriff (PDF)

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2019-05, Vol.30 (5), p.871-873

2019

Volltextzugriff (PDF)

Systematic review: evidence‐based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials

Alimentary pharmacology & therapeutics, 2006-06, Vol.23 (11), p.1535-1547

2006

Volltextzugriff (PDF)

Intention‐to‐treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation

Hepatology (Baltimore, Md.), 1999-12, Vol.30 (6), p.1434-1440

1999

Volltextzugriff (PDF)

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

Hepatology (Baltimore, Md.), 2003-02, Vol.37 (2), p.429-442

2003

Volltextzugriff (PDF)

Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation

Gut, 2002-01, Vol.50 (1), p.123-128

2002

Volltextzugriff (PDF)

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

Annals of oncology, 2018-10, Vol.29 (10), p.2121-2128

2018

Volltextzugriff (PDF)

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

ESMO open, 2023-06, Vol.8 (3), p.101567-101567, Article 101567

2023

Volltextzugriff (PDF)

Corrigendum to “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology 29 suppl. 4 (2018) v238–iv255]

Annals of oncology, 2022-06, Vol.33 (6), p.666-666

2022

Volltextzugriff (PDF)

Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma

Hepatology (Baltimore, Md.), 2001-05, Vol.33 (5), p.1124-1129

2001

Volltextzugriff (PDF)

New aspects of diagnosis and therapy of hepatocellular carcinoma

Oncogene, 2006-06, Vol.25 (27), p.3848-3856

2006

Volltextzugriff (PDF)

LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

Annals of oncology, 2022-09, Vol.33, p.S1401

2022

Volltextzugriff (PDF)

Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials

Hepatology (Baltimore, Md.), 1999-01, Vol.29 (1), p.62-67

1999

Volltextzugriff (PDF)

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)

Annals of oncology, 2018-10, Vol.29, p.viii208-viii208

2018

Volltextzugriff (PDF)

Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution

Hepatology (Baltimore, Md.), 1998-06, Vol.27 (6), p.1578-1583

1998

Volltextzugriff (PDF)

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

Annals of oncology, 2021-06, Vol.32 (6), p.801-805

2021

Volltextzugriff (PDF)

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)

Annals of oncology, 2018-06, Vol.29, p.v122-v122

2018

Volltextzugriff (PDF)

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

Hepatology (Baltimore, Md.), 2000-01, Vol.31 (1), p.54-58

2000

Volltextzugriff (PDF)

Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)

Annals of oncology, 2019-07, Vol.30, p.iv133-iv133

2019

Volltextzugriff (PDF)

Liver transplantation for small hepatocellular carcinoma: The tumor‐node‐metastasis classification does not have prognostic power

Hepatology (Baltimore, Md.), 1998-06, Vol.27 (6), p.1572-1577

1998

Volltextzugriff (PDF)

Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis

Hepatology (Baltimore, Md.), 1994-12, Vol.20 (6), p.1495-1501

1994

Volltextzugriff (PDF)

Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective

Hepatology (Baltimore, Md.), 2001-05, Vol.33 (5), p.1073-1079

2001

Volltextzugriff (PDF)

Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy

Hepatology (Baltimore, Md.), 2000-04, Vol.31 (4), p.1019-1021

2000

Volltextzugriff (PDF)

Hepatitis B Virus Genotype and Mutants: Risk Factors for Hepatocellular Carcinoma

JNCI : Journal of the National Cancer Institute, 2008-08, Vol.100 (16), p.1121-1123

2008

Volltextzugriff (PDF)

1 – 25 von 828

Suche als RSS-Feed

Aktive Filter

KollektionEZB Electronic Journals Library

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(213)
Mit Volltextzugriff
(796)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(112)
Science & Technology
(100)
Life Sciences & Biomedicine
(92)
Male
(60)
Female
(54)
Middle Aged
(43)
Gastroenterology & Hepatology
(40)
Biological And Medical Sciences
(36)
Medical Sciences
(34)
Aged
(31)
Adult
(29)
Oncology
(27)
Tumors
(23)
Liver Neoplasms - Pathology
(20)
Carcinoma, Hepatocellular - Pathology
(19)
Carcinoma, Hepatocellular - Therapy
(18)
Hepatocellular Carcinoma
(17)
Liver Cancer
(17)
Liver Neoplasms - Therapy
(17)
Prognosis
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Systematic review: evidence‐based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials

Intention‐to‐treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

Corrigendum to “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology 29 suppl. 4 (2018) v238–iv255]

Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma

New aspects of diagnosis and therapy of hepatocellular carcinoma

LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)

Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)

Liver transplantation for small hepatocellular carcinoma: The tumor‐node‐metastasis classification does not have prognostic power

Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis

Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective

Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy

Hepatitis B Virus Genotype and Mutants: Risk Factors for Hepatocellular Carcinoma

Aktive Filter

Suchergebnisse filtern